Mounjaro and Zepbound contain the same active ingredient — tirzepatide — but they are FDA-approved for different uses: Mounjaro for type 2 diabetes and Zepbound for chronic weight management, plus certain adults with obstructive sleep apnea and obesity. Their dose strengths and once-weekly injection schedule are essentially the same, but the label, insurance pathway, and clinical goal behind the prescription can be very different.
That distinction matters because people often hear about tirzepatide as if it were one product. Biologically, it is one molecule. Practically, the brand name on the box can affect why it was prescribed, what your plan covers, what outcomes your prescriber is monitoring, and how you organize your dose history.
The Short Version: Same Molecule, Different Label
Tirzepatide is a once-weekly injectable medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes and as Zepbound for weight-management indications.
The FDA label for Mounjaro describes it as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The Zepbound prescribing information describes chronic weight management in eligible adults and includes an indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
So if someone asks, "Is Zepbound just Mounjaro?" the accurate answer is: same active ingredient, different FDA-approved use and product label.
| Question | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Primary FDA-approved use | Type 2 diabetes glycemic control | Chronic weight management; OSA with obesity |
| Schedule | Once weekly injection | Once weekly injection |
| Dose strengths | 2.5 mg through 15 mg | 2.5 mg through 15 mg |
| Starting dose | 2.5 mg once weekly | 2.5 mg once weekly |
| Maximum dose | 15 mg once weekly | 15 mg once weekly |
Dosing: The Ladder Is the Same
Both products start at 2.5 mg once weekly for four weeks, then increase to 5 mg once weekly. If additional effect is needed and tolerated, the dose can be increased in 2.5 mg increments after at least four weeks on the current dose, up to 15 mg once weekly.
The 2.5 mg dose is a starting dose intended to help your body adjust. It is not typically treated as the long-term therapeutic dose. That is why your first month may feel more like a lead-in period than a full maintenance phase.
For a deeper step-by-step explanation, see our tirzepatide dosing schedule. If you are logging the medication itself, the relevant tracker pages are Mounjaro tracker, Zepbound tracker, and tirzepatide tracker.
Why the Brand Name Still Matters
Even when the molecule and dose ladder match, the brand name is not just cosmetic.
Your treatment goal may differ. With Mounjaro, your prescriber may focus heavily on A1C, fasting glucose, hypoglycemia risk with other diabetes medications, and cardiometabolic markers. With Zepbound, the central goals may include weight change, waist circumference, sleep apnea symptoms, and long-term tolerability.
Insurance coverage may differ. Many insurance plans separate diabetes drugs from anti-obesity medications. A plan may cover Mounjaro for type 2 diabetes but exclude Zepbound for weight management, or require different prior authorization criteria for each.
Your medical record may read differently. A prescription written for diabetes care and a prescription written for obesity treatment can trigger different documentation, follow-up questions, and pharmacy workflows.
Your expectations may differ. Someone starting Mounjaro for A1C improvement may judge success differently than someone starting Zepbound for weight management. Both may see weight and metabolic effects, but the labeled indication frames the clinical conversation.
Can You Switch Between Mounjaro and Zepbound?
Sometimes, but it should be handled by your prescriber and pharmacy. Because the active ingredient is the same, a clinician may consider brand switching when coverage, supply, or indication changes. That does not mean you should treat the boxes as interchangeable on your own.
If you switch brands, confirm the exact dose, next injection date, and reason for the switch. The most important practical risk is accidentally duplicating doses or misunderstanding whether your schedule resets. Keep a written record of the last injection date, brand, dose, and injection site so the transition is clear.
If your switch is from semaglutide rather than between tirzepatide brands, read Switching From Ozempic to Mounjaro, because semaglutide and tirzepatide doses do not convert.
Tracking Mounjaro or Zepbound Without Mixing Up Your History
Tirzepatide titration can run for months. You may pause at a dose, step up, step down for side effects, or change brand names because of insurance. Memory is a poor system for that much detail.
A useful log should show:
- the exact medication name and dose,
- the injection date and site,
- any dose changes,
- weight or glucose trends you are following,
- side effects around step-up weeks.
OffGrid Dose is built for that kind of record. You can track the tirzepatide schedule, rotate injection sites, and keep a continuous timeline if your brand changes. The privacy-first GLP-1 tracker. Everything stays on your iPhone — no accounts, no cloud. Explore the features or start with the brand page that fits your prescription: Mounjaro tracker or Zepbound tracker.
Frequently Asked Questions
Are Mounjaro and Zepbound the same drug?
They contain the same active ingredient, tirzepatide. The difference is the FDA-approved indication and product label: Mounjaro is approved for adults with type 2 diabetes, while Zepbound is approved for chronic weight management and certain adults with obstructive sleep apnea and obesity.
Is Zepbound stronger than Mounjaro?
Not by molecule or dose strength. Both use tirzepatide and the same 2.5 mg to 15 mg dose range. Individual results depend on dose, adherence, medical history, nutrition, activity, and tolerability.
Do Mounjaro and Zepbound have the same side effects?
They share the same active ingredient, so their common side effects overlap substantially, especially gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Your personal risk depends on your dose, titration pace, and health history.
Can my pharmacy substitute one for the other?
Do not assume so. Even with the same active ingredient, substitutions depend on the prescription, state law, insurance rules, availability, and prescriber instructions. Ask your pharmacist and prescriber before changing brands.
Which tracker should I use if I switch brands?
Use a tracker that preserves the full tirzepatide timeline instead of forcing you to start over. OffGrid Dose supports tirzepatide tracking across brand-specific contexts, so your dose history remains understandable.
This article is for general educational purposes only and is not medical advice. Tirzepatide should be used only as prescribed, and decisions about brand, dose, indication, or switching should be made with your healthcare provider or pharmacist using the current FDA-approved label for your specific product.
Related Articles
Track this with OffGrid Dose
Log every dose, rotate injection sites, and watch your weight trend — all private and on-device.
Tirzepatide tracker →